Document is current

Article History

Received: 17 May 2021

Accepted: 14 February 2022

First Online: 24 February 2022

Declarations

:

: Participation in this study was entirely voluntary. Verbal informed consent was sought (confirmed at the beginning of each interview and defined within the interview schedule) and participants also returned a signed Participant Information and Consent Form (PICF) via email. Human Ethics approval was granted by Monash Health Human Research Ethics Committee (Monash Health Ref: RES-19–0000-704L) and Monash University Human Research Ethics Committee (Ref: 22618). All methods were performed in accordance with the National Statement on Ethical Conduct Involving Humans (updated 2018) and the Australian Code for Responsible Conduct of Research [49, 50].

: Participants were informed via the PICF that the study would be submitted for publication and thus gave informed consent for publication of de-identified information.

: SG is employed by Monash University and receives funding from National Health and Medical Research Council (NHMRC), Medical Research Future Fund (MRFF), and the Victorian Department of Health and Human Services. She has no declaration of interest specific to the research reported in this paper. SZ reports payment to institution (Monash University) from Eli Lilly Australia Ltd, Boehringer-Ingelheim, Merck Sharp & Dohme (MSD) Australia, AstraZeneca, Novo Nordisk, Sanofi, Servier, for work outside the submitted work. The other authors declare no relevant declarations of interest with regards to this manuscript.